Nanshan School, Guangzhou Medical University, Jingxiu Road, Panyu District, Guangzhou, 511436, China.
Department of Thoracic Surgery and Oncology, National Center for Respiratory Health, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, China.
Lung. 2024 Oct;202(5):501-511. doi: 10.1007/s00408-024-00737-8. Epub 2024 Aug 24.
Pneumonia is a common lower respiratory tract infection, and early diagnosis is crucial for timely treatment and improved prognosis. Traditional diagnostic methods for pneumonia, such as chest imaging and microbiological examinations, have certain limitations. Exhaled volatile organic compounds (VOCs) detection, as an emerging non-invasive diagnostic technique, has shown potential application value in pneumonia screening.
A systematic search was conducted on PubMed, Embase, Cochrane Library, and Web of Science, with the retrieval time up to March 2024. The inclusion criteria were diagnostic studies evaluating exhaled VOCs detection for the diagnosis of pneumonia, regardless of the trial design type. A meta-analysis was performed using a bivariate model for sensitivity and specificity.
A total of 14 diagnostic studies were included in this meta-analysis. The pooled results demonstrated that exhaled VOCs detection had a combined sensitivity of 0.94 (95% CI: 0.92-0.95) and a combined specificity of 0.83 (95% CI: 0.81-0.84) in pneumonia screening, with an area under the summary receiver operating characteristic (SROC) curve (AUC) of 0.96. The pooled diagnostic odds ratio (DOR) was 104.37 (95% CI: 27.93-390.03), and the pooled positive and negative likelihood ratios (LR) were 8.98 (95% CI: 3.88-20.80) and 0.11 (95% CI: 0.05-0.22), indicating a high diagnostic performance.
This study highlights the potential of exhaled VOCs detection as an effective, non-invasive screening method for pneumonia, which could facilitate future diagnosis in pneumonia. Further high-quality, large-scale studies are required to confirm the clinical utility of exhaled VOCs detection in pneumonia screening.
PROSPERO, Review no. CRD42024520498.
肺炎是一种常见的下呼吸道感染,早期诊断对于及时治疗和改善预后至关重要。传统的肺炎诊断方法,如胸部影像学和微生物学检查,存在一定的局限性。呼出气挥发性有机化合物(VOCs)检测作为一种新兴的非侵入性诊断技术,在肺炎筛查中显示出了潜在的应用价值。
系统检索了 PubMed、Embase、Cochrane 图书馆和 Web of Science 数据库,检索时间截至 2024 年 3 月。纳入标准为评估呼出气 VOCs 检测用于肺炎诊断的诊断研究,无论试验设计类型如何。使用双变量模型进行敏感性和特异性的荟萃分析。
本荟萃分析共纳入 14 项诊断研究。汇总结果显示,呼出气 VOCs 检测在肺炎筛查中的合并敏感性为 0.94(95%CI:0.92-0.95),特异性为 0.83(95%CI:0.81-0.84),汇总受试者工作特征(SROC)曲线下面积(AUC)为 0.96。汇总诊断比值比(DOR)为 104.37(95%CI:27.93-390.03),汇总阳性和阴性似然比(LR)分别为 8.98(95%CI:3.88-20.80)和 0.11(95%CI:0.05-0.22),表明诊断性能较高。
本研究强调了呼出气 VOCs 检测作为一种有效、非侵入性的肺炎筛查方法的潜力,这可能有助于未来肺炎的诊断。需要进一步开展高质量、大规模的研究,以证实呼出气 VOCs 检测在肺炎筛查中的临床应用价值。
PROSPERO,注册号 CRD42024520498。